�Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetical and therapeutic skin health systems, proclaimed the launch of SoluCLENZ Rx Gel�, a solubilized benzoyl peroxide (BPO) gelatin for the treatment of acne. SoluCLENZ Rx Gel will be available only by prescription starting in mid-August and will be promoted by Obagi Medical's specialty dermatology sales force.
SoluCLENZ Rx Gel contains 5% solubilized BPO, which enhances the follicular penetration of BPO. Traditional BPO formulations ar poorly soluble and many contain micro and macro instruction crystals that may be too large to participate the follicles and treat acne at the reference. Based on a serial publication of clinical studies conducted over the past several years, Obagi Medical has consistently demonstrated that SoluCLENZ Rx Gel is a novel treatment alternative that provides clinically significant lesion reductions that are like to the leading prescription BPO/antibiotic combination products, without the usage of a topical antibiotic drug.
"At Obagi Medical, we pride ourselves on organism business partners with physicians and delivering innovative skin health products," said Steven Carlson, Chief Executive Officer of Obagi Medical Products. "With the launch of our solubilized BPO applied science as a prescription-only product in the pharmacy channel, we continue to offer more options to our physicians. The launch of SoluCLENZ Rx Gel will help dermatologists not solely meet, only exceed their patients' expectations."
About Solubilized Benzoyl Peroxide Obagi Medical's proprietary, solubilized BPO, known as SoluZyl Technology, is 1/10,000 the size of it of whatsoever other BPO molecule available, so it can perforate deep into the solution of the follicle and treat acne where it starts. Obagi Medical's solubilized 5% BPO is clinically proven to kill more P. acnes bacteria faster than the leading colloidal gel BPO/antibiotic combination product.
About SoluCLENZ SoluCLENZ Rx is a 5% solubilized BPO gel that uses proprietary ingredients and is indicated for the treatment of acne.
Of the patients who experient expected signs and symptoms of treatment (erythema, peeling, dryness, burning at the stake and/or stinging) during clinical studies, the majority of cases were mild to moderate, occurred during the early weeks of treatment and decreased or resolved over fourth dimension. Although rare, allergic reactions have been reported with topical benzoyl peroxide therapy.
About Obagi Medical Products, Inc. Obagi Medical Products develops and commercializes skin health products for the dermatology, formative surgery, and related aesthetic markets. Using its Penetrating Therapeutics� technologies, Obagi Medical's products ar designed to improve incursion of agents across the skin barrier for vulgar and visible skin conditions in grownup skin including chloasma, mask of pregnancy, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm�, 1988; Obagi-C� Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi� Professional-C (a phone line of highly stable vitamin C serums), 2005; Obagi� Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm� optic treatment and Obagi CLENZIderm� M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm� M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm� D�colletage System, January 2008 and SoluCLENZ Rx Gel for the pharmacy channel in August 2008.
hTTP://www.obagi.com
Forward-Looking Statements There are advanced statements contained herein, which can be identified by the manipulation of advanced terminology such as the words "believes," "expects," "crataegus oxycantha," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such innovative statements involve known and unknown risks, uncertainties and other factors that crataegus laevigata cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, simply are non limited to possibility that our ingress into the pharmacy-dispensed communication channel will be unsuccessful and that few physicians will opt to prescribe pharmacy-dispensed SoluCLENZ Rx Gel, the intense contest our products face and will grimace in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and judicial proceeding that could adversely dissemble the profitability of or our ability to sell our products, the possibility that our products whitethorn cause unwanted side effects and the fact that our ability to commercially distribute our products may be importantly harmed if the regulative environment governance our products changes. A more elaborate discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year over December 31, 2007. These factors should be considered carefully and readers ar cautioned non to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this weigh release is as of the date of this press handout and Obagi Medical Products does non intend to update this information.
Obagi Medical Products, Inc.
More info
